UK recommendations issued to realize cell and gene therapy potential
A report published by the Cell & Gene Collective, based on the findings of an expert commission, has offered recommendations to ensure the UK’s leadership in cell and gene therapies (CGTs) and urgently remove barriers to their adoption.
The Cell & Gene Collective is an alliance of biopharma companies with an interest in CGTs. Member companies are Bayer (BAYN: DE), Johnson & Johnson (NYSE: JNJ), Gilead Sciences (Nasdaq: GILD), Orchard Therapeutics (Nasdaq: ORTX) and Vertex Pharmaceuticals (Nasdaq: VRTX).
Its report, entitled Tomorrow’s Science, Today’s National Health Service (NHS): Unleashing a new era of medicine, makes 25 immediate and medium-term recommendations to foster UK leadership in the sector, build strong foundations to improve access, and realize a new era of medicine.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
Free
7 day trial access
- All the news that moves the needle in pharma and biotech
- Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
- Receive The Pharma Letter daily news bulletin, free forever.
Become a subscriber
£820
Or £77 per month
- Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
- Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
- Daily roundup of key events in pharma and biotech.
- Monthly in-depth briefings on Boardroom appointments and M&A news.
- Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
More on this story...
Today's issue
Company Spotlight
More Features in Biotechnology
Copyright © The Pharma Letter 2025 | Headless Content Management with Blaze